Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

At Fabre-Kramer Pharmaceuticals, their goal is to develop and bring to market advanced new medications to help physicians treat their patients' unmet medical needs.Fabre-Kramer Pharmaceuticals, Inc. (“FKP” or the “Company”), was formed to identify, develop and commercialize psychotropic drugs with significant market potential. The Company’s principals have over 40 years of experience in the clinical development of psychotropic drugs and have conducted pivotal studies of many drugs approved by the FDA in psychiatry. They have conducted studies in depression, anxiety, schizophrenia, bipolar disorder, social phobia and sleep disorders. They also have over 40 years of experience in in-patient and out-patient psychiatry, have intimate knowledge of the treatment of Central Nervous System (“CNS”) disorders and have analyzed many potential psychotropic compounds from the standpoint of receptor activity, efficacy, tolerability, side effect/benefit ratio, formulation, ease of administration, cost, and ease of manufacturing.

Manufactures pharmaceuticals

Nanjing Mingde New Drug Research and Development Co., Ltd., established on 2011-12-16, The scope of business includes engaging in pharmaceutical,Biological product,medical instruments,food development,Research;Environmental and pesticide testing services;Pharmaceutical Small Molecule Compound Library,Preclinical studies of drug leads and drug products,Technology development related to process development and clinical research,Technology introduction,Technical Services,Technical consulting and technology transfer,related technology,Licensing of Patents and Intellectual Property,Achievement Transformation and Transfer;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval)

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

DeuteRx is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The company specializes in the use of deuterium to chiral switch drugs that are a mixture of interconverting stereoisomers. This approach has been applied to >15 APIs at 2 companies since 2010.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Syngenta AG is a global company that produces agrochemicals and seeds and is based in Basel, Switzerland. As a biotechnology company, it conducts genomic research. It was formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. As of 2014 Syngenta is the world’s largest crop chemical producer As of 2009 it ranked third in seeds and biotechnology sales. Sales in 2015 were approximately US$13.4 billion, over half of which were in emerging markets. It is owned by ChemChina, a Chinese state-owned enterprise.

Nanjing Cavendish Bioengineering Technology Co., Ltd., established on 2006-11-15, Business scope includes pharmaceutical products,Chemical Products,Technical development of biological products,technical consulting,technology transfer;Biochemicals(Does not contain drugs),Chemical product sales;Self-operated and agent import and export business of various commodities and technologies(Except where the state restricts enterprises to operate or prohibits the import and export of commodities and technologies);(Branches licensed to operate under the)Processing of pharmaceutical and chemical intermediate products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Drug Wholesale;pharmaceutical production;Drug import and export;Drug internet information service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Good health and a happy life is something all people rightly aspire to. They believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all the ability to innovate. Innovation and continuous improvement are the heartbeat of their company. Their mission is to make health care more affordable, increasing access to important medicines through the provision of high quality small molecule generics, and new biological and new chemical entities.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Pharmaceuticals

Part of Hansoh Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd. is a company headquartered in Jiangsu, China, that manufactures and distributes pharmaceutical products.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

Ildong Pharmaceutical Co., Ltd. engages in the manufacture and sale of medicines, ingredients for medicines, health supplements and special nutritional products. Its products include vitamins, antibiotics, gastric ulcer medicine, peptic ulcerative agents, and diet pills. The company was founded on August 1, 2016 and is headquartered in Seoul, South Korea.